5.4418

2.18% -0.1082

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $5.4418, with a volume of 880.16K. It is down -2.18% in the last 24 hours and down -12.86% over the past month. Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Previous Close:

$5.55

Open:

$5.46

24h Volume:

880.16K

Relative Volume:

0.36

Market Cap:

$419.34M

Revenue:

$409.00K

Net Income/Loss:

$-101.35M

P/E Ratio:

-3.3182

EPS:

-1.64

Net Cash Flow:

$-71.49M

1W Performance:

-2.88%

1M Performance:

-12.86%

6M Performance:

-31.10%

1Y Performance:

-50.24%

1-Day Range:

$5.34

$5.62

1-Week Range:

$5.15

$5.6439

52-Week Range:

$5.15

$11.16

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	5.49	419.34M	409.00K	-101.35M	-71.49M	-1.64
VRTX Vertex Pharmaceuticals Inc	499.31	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.13	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.71	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 12, 2025

Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia

Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 09, 2025

Altimmune, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025

Mar 07, 2025

Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 07, 2025

HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World

Mar 07, 2025

Mar 06, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times

Mar 06, 2025

Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq

Mar 06, 2025

Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan

Mar 06, 2025

Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World

Mar 06, 2025

Mar 05, 2025

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire

Mar 05, 2025

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire

Mar 05, 2025

Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia

Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India

Mar 04, 2025

Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 04, 2025

Mar 03, 2025

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025

(ALT) On The My Stocks Page - Stock Traders Daily

Mar 03, 2025

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Mar 03, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference - The Manila Times

Mar 03, 2025

Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025

B. Riley Has Optimistic Outlook of Altimmune FY2025 Earnings - Defense World

Mar 03, 2025

How Will Altimmune's Upcoming Leerink Conference Appearance Impact Its Clinical Pipeline Strategy? - StockTitan

Mar 03, 2025

Mar 02, 2025

ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc. - ACCESS Newswire

Mar 02, 2025

Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 02, 2025

William Blair Begins Coverage on Altimmune (NASDAQ:ALT) - Defense World

Mar 02, 2025

Mar 01, 2025